Compare FANG & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | IDXX |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4B | 57.1B |
| IPO Year | 2012 | 1996 |
| Metric | FANG | IDXX |
|---|---|---|
| Price | $196.94 | $573.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 9 |
| Target Price | $198.11 | ★ $715.00 |
| AVG Volume (30 Days) | ★ 3.3M | 450.1K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 22.59 |
| EPS | 5.73 | ★ 13.08 |
| Revenue | ★ $15,026,000,000.00 | $4,303,702,000.00 |
| Revenue This Year | $2.67 | $10.88 |
| Revenue Next Year | $3.73 | $8.59 |
| P/E Ratio | ★ $33.55 | $43.97 |
| Revenue Growth | ★ 35.79 | 10.42 |
| 52 Week Low | $114.00 | $356.25 |
| 52 Week High | $194.68 | $769.98 |
| Indicator | FANG | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 74.57 | 33.25 |
| Support Level | $136.41 | $567.62 |
| Resistance Level | N/A | $657.26 |
| Average True Range (ATR) | 5.70 | 15.80 |
| MACD | 1.11 | -1.22 |
| Stochastic Oscillator | 89.57 | 7.45 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.